OrSense is a medical device company developing non-invasive glucose
monitoring systems for people with diabetes. The Company’s products are
based on its proprietary Occlusion Spectroscopy technology. OrSense also
develops and markets non-invasive monitoring products for other critical
blood parameters, such as hemoglobin.
The Company's first commercial product is CE approved for monitoring
hemoglobin and hematocrit. OrSense’s intellectual property portfolio
consists of 20 granted patents, with over 25 additional applications in
process. Investors include Israel Health Care Ventures and STAR Ventures.
Website at www.orsense.com